Ненасыщенные жирные кислоты семейства омега-6

The Comprehensive Blood Analysis for Omega-3 and Omega-6 Polyunsaturated Fatty Acids (PUFA profile) quantifies circulating long‑chain omega‑3 and omega‑6 fatty acids to characterize their balance. The assay supports diagnosis, risk assessment, and management decisions in ischemic heart disease, ischemic stroke, and select cancers including pancreatic, prostate, and breast malignancies. This test also informs nutritional evaluation and therapeutic planning by documenting baseline status and tracking response to diet modification or omega‑3 supplementation, particularly when interpreted alongside other lipid measurements in cardiometabolic care.

Omega‑3 and omega‑6 fatty acids are polyunsaturated fatty acids (PUFAs) characterized by two or more double bonds; the first double bond lies three (omega‑3) or six (omega‑6) carbons from the terminal methyl group. While some PUFAs derive from endogenous synthesis, several are dietary essentials: linoleic acid (omega‑6) and alpha‑linolenic, eicosapentaenoic (EPA), and docosahexaenoic (DHA) acids (omega‑3). Major sources of omega‑3 include fatty marine fish (trout, salmon, mackerel), marine algae, and flaxseed oil; omega‑6 PUFAs are abundant in sunflower, soybean, poppy, and corn oils. Reported physiologic roles differ by class. In infancy, omega‑3 PUFAs support neurodevelopment and visual cortical function. EPA and DHA have been associated with attenuated age‑related cognitive decline, reduced oncologic risk, and favorable metabolic effects in diabetes. The most consistent evidence concerns cardiovascular health: omega‑3 fatty acids lower triglycerides and exhibit antithrombotic, fibrinolytic, antiarrhythmic, and anti‑inflammatory actions. Dietary guidance commonly recommends increasing omega‑3 intake to 10% of total daily caloric intake. Omega‑3 preparations are incorporated into therapeutic regimens for ischemic heart disease and stroke, and measuring blood concentrations can help monitor treatment, especially when used with agents that have antiarrhythmic or antithrombotic effects (eg, aspirin, beta‑blockers). Omega‑6 PUFAs contribute to brain function, skin cell development, hair and bone growth, and metabolic regulation. Excess omega‑6 intake has been linked to immune suppression, hypertension and other cardiovascular disturbances, heightened inflammation, and potential oncologic risk. Increasing emphasis is placed on the omega‑3/omega‑6 ratio rather than isolated concentrations; a ratio of 1/1 to 5/1 is cited as favorable for the prevention of cardiovascular, skeletal, and oncologic diseases. Achieving this range can be challenging given the predominance of omega‑6 fatty acids in contemporary diets, so concurrent measurement of both classes is used to assess balance. PUFA metabolism varies with sex, age, physical activity, dietary patterns, comorbid conditions, and medication use. Accordingly, results require interpretation in conjunction with clinical history and complementary laboratory data.